Abstract:OBJECTIVE:To screen potential pan-cancer biomarkers based on The Cancer Genome Atlas (TCGA) database, and to provide help for the diagnosis and prognosis assessment of a variety of cancers. METHODS:"GDC Data Transfer Tool" and "GDCRNATools" packages were used to obtain TCGA database. After data sorting, a total of 13 cancers were selected for further analysis. False disco-very rate (FDR) < 0.05 and fold change (FC) >1.5 were used as the differential expression criteria to screen genes and miRNAs that were up- or down-regulated in all the 13 cancers. In the receiver operating characteristic curve (ROC curve), the area under the curve (AUC), the best cut-off value and the corresponding sensitivity and specificity were used to reflect diagnostic significance. The Kaplan-Meier method was used to calculate the survival probability and then the log-rank test was performed. Hazard ratio (HR) was calculated to reflect prognostic evaluation significance. DAVID tool were used to perform GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis for differentially expressed genes. STRING and TargetScan tools were used to analyze the regulatory network of differentially expressed genes and miRNAs. RESULTS:A total of 48 genes and 2 miRNAs were differentially expressed in all the 13 cancers. Among them, 25 genes were up-regulated, 23 genes and 2 miRNAs were down-regulated. Most differentially expressed genes and miRNAs had good ability to distinguish between the cases and controls, with AUC, sensitivity and specificity up to 0.8-0.9. Survival analysis results show that differentially expressed genes and miRNAs were significantly associated with patient survival in a variety of cancers. Most up-regulated genes were risk factors for patient survival (HR>1), while most down-regulated genes were protective factors for patient survival (0 < HR < 1). The enrichment analysis of GO and KEGG showed that the differentially expressed genes were mostly enriched in biological events related to cell proliferation. In the regulatory network analysis, a total of 13 differentially expressed genes and 2 differentially expressed miRNAs had regulatory and interaction relationships. CONCLUSION:The 48 genes and 2 miRNAs that were differentially expressed in 13 cancers may serve as potential pan-cancer biomarkers, providing help for the diagnosis and prognosis evaluation of a variety of cancers, and providing clues for the development of broad-spectrum tumor therapeutic targets.

Screening of Differentially Expressed Genes of Prostate Cancer with DNA Microarray

Screening for differential genes of the prostate cancer and bioinformatics analysis of their interaction

Analysis of Whole Genomic Expression Profiles and Screening of the Key Signaling Pathways Associated with Pancreatic Cancer.

Investigation of the Molecular Mechanisms Underlying Metastasis in Prostate Cancer by Gene Expression Profiling

Bioinformatics analysis of differential gene expression and signal pathway in prostate cancer

Identifying differentially expressed genes and small molecule drugs for prostate cancer by a bioinformatics strategy

Identification Of Differentially Expressed Genes Between Mucinous Adenocarcinoma And Other Adenocarcinoma Of Colorectal Cancer Using Bioinformatics Analysis

An integrative bioinformatics study of gene expression profile in prostate cancer

Analysis of Related Gene Expression in Prostate Carcinoma by Cdna Microarray

A Cdna Microarray Study on Differentially Expressed Genes in Prostate Cancer

Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods

Identification of Pathologic and Prognostic Genes in Prostate Cancer Based on Database Mining

The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer.

Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas.

Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray.

Identifying novel prostate cancer associated pathways based on integrative microarray data analysis

Study of Differentially Expressed Genes in Pancreatic Cancer by cDNA Microarray

[Exploratory Screening of Potential Pan-Cancer Biomarkers Based on the Cancer Genome Atlas Database].

Analyzing the LncRNA, miRNA, and mRNA Regulatory Network in Prostate Cancer with Bioinformatics Software.

Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer.

Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population